一分钟看懂
这是一项关于鼻咽癌的III 期研究，登记的药物或干预包括BL-B01D1；PD-1 monoclonal antibody；cisplatin；gemcitabine，当前状态为尚未开始招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BL-B01D1；PD-1 monoclonal antibody；cisplatin；gemcitabine · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- 1. Voluntarily sign the informed consent form and comply with the protocol requirements;
- 2. Age ≥ 18 years;
- 3. Expected survival time ≥ 3 months;
- 4. Trial participants with nasopharyngeal carcinoma confirmed by histopathology and/or cytology, either initially diagnosed with metastatic disease or relapsed after curative-intent treatment;
- 5. Agree to provide tumor tissue samples obtained at or after the diagnosis of recurrent or metastatic disease;
- 6. Must have at least one measurable lesion as defined by RECIST v1.1;
- 7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- 8. Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07783321；登记信息更新于 2026-09-15。